

(51) International Patent Classification:
A61K 47/68 (2017.01) *A61P 35/00* (2006.01)(21) International Application Number:
PCT/US2023/029434(22) International Filing Date:
03 August 2023 (03.08.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/394,912 03 August 2022 (03.08.2022) US(71) Applicants: **SEAGEN INC.** [US/US]; 21823 30th Drive SE, Bothell, Washington 98021 (US). **REGENTS OF THE UNIVERSITY OF MINNESOTA** [US/US]; 600 McNamara Alumni Center, 200 Oak Street SE, Minneapolis, Minnesota 55455 (US).(72) Inventors: **WANG, Kung-Pern**; c/o Seagen Inc., 21823 30th Drive SE, Bothell, Washington 98021 (US). **SMITH, Alyson**; c/o Seagen Inc., 21823 30th Drive SE, Bothell, Washington 98021 (US). **NEUMANN, Christopher Scott**; c/o Seagen Inc., 21823 30th Drive SE, Bothell, Washington 98021 (US). **GARDAL, Shyra J.**; c/o Seagen Inc., 21823 30th Drive SE, Bothell, Washington 98021 (US). **FERGUSON, David M.**; c/o Regents of the University of Min-

nesota, McNamara Alumni Center, 200 Oak Street SE, Suite 600, Minneapolis, Minnesota 55455 (US).


(74) Agent: **HARWOOD, PH.D., Melissa M.** et al.; DLA PIPER LLP (US), 701 Fifth Avenue, Suite 6900, Seattle, Washington 98104-7029 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: IMMUNOSTIMULATORY ANTI-PD-L1-DRUG CONJUGATES

○ Untreated
● Immune-targeted cmpd 4, 2 mg/kg
● Immune-targeted cmpd 3, 2 mg/kg
○ non-targeted cmpd 4, 2 mg/kg
○ non-targeted cmpd 3, 2 mg/kg



○ Immune-targeted cmpd 3, 2 mg/kg
● non-targeted cmpd 4, 2 mg/kg
● non-targeted cmpd 3, 2 mg/kg
○ Untreated
○ Immune-targeted cmpd 4, 2 mg/kg




FIG. 10

(57) Abstract: The present disclosure provides compounds and methods useful for treating a range of cancers. The compounds include antibody drug conjugates (ADCs) configured to selectively activate immune responses within tumor microenvironments and reverse tumor associated macrophage-mediated immunosuppression. Particular aspects of the disclosure relate to TLR7/8 agonists conjugated to tumor and immune cell-targeted antibodies.

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*